NCT05447039View on ClinicalTrials.gov

Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

March 30, 2021

Conditions
Post COVID-19
Interventions
DRUG

Montelukast Sodium Tablets

intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days

Trial Locations (1)

71515

Aliae Mohamed-Hussein, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT05447039 - Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough | Biotech Hunter | Biotech Hunter